Medicare GLP-1 Bridge: Eligibility and the $50 Copay
The GLP-1 Bridge runs July 1, 2026 through December 31, 2027 for eligible Medicare drug-plan beneficiaries. It is a separate demonstration, with a $50 monthly drug copay. Check both clinical eligibility and the actual formulation before relying on that price.
Covered products and eligibility
Medicare’s current list includes Foundayo tablets, Wegovy injection/tablets and Zepbound KwikPen; single-dose Zepbound vials and pens are excluded. Adults need qualifying Part D coverage and BMI at least 35, or BMI at least 30 with HFpEF, uncontrolled hypertension or stage 3 a-or-higher CKD, or BMI at least 27 with prediabetes, prior heart attack/stroke or symptomatic peripheral artery disease.
People already receiving Part D-covered GLP-1 s, or with type 2 diabetes, moderate-to-severe sleep apnea or noncirrhotic MASH with moderate-to-advanced liver scarring consistent with F2–F3 fibrosis, are directed to the ordinary Part D pathway. Prescribers should apply the current CMS diagnosis criteria; simple fatty liver alone does not establish this MASH pathway. Eligibility is separate from product-specific medical suitability.
What the copay does and does not cover
CMS explains that Bridge drugs sit outside ordinary Part D payment. The deductible does not apply, and copays do not count toward Part D out-of-pocket limits. Extra Help cannot reduce them, and Medicare Prescription Payment Plan installments do not apply. Clinical services may cost separately. For more on this topic, see our guide to foundayo cost.
Prescription and authorization
Ask your prescriber to assess suitability, send the prescription and complete prior authorization when requested. The provider certifies diet/exercise-program use. The pharmacy processes the eligible fill; your plan need not opt in for 2026. No separate enrollment or automatic prescription is promised.
Plan beyond the demonstration
The demonstration has a scheduled end. Continuing $50 access after 2027 is not guaranteed; CMS says BALANCE will not launch in Medicare Part D in 2027. Compare your actual alternatives without assuming compounded drugs are universally appropriate or every telehealth platform excludes Medicare patients.
Related reading
- complete GLP-1 guide
- GLP-1 for weight loss
- Wegovy cost guide
- Zepbound cost guide
- Foundayo guide
- Foundayo cost breakdown
- Ozempic cost
- Mounjaro cost
- which GLP-1 is best for weight loss
- semaglutide vs tirzepatide
- GLP-1 insurance coverage
- GLP-1 side effects
- telehealth weight loss programs
- GLP-1 telehealth pricing
- cheapest semaglutide options
- whether compounded semaglutide is legal in 2026
Frequently Asked Questions
A temporary demonstration providing specified GLP-1 s to eligible Part D beneficiaries outside normal Part D payment.
Foundayo tablets, Wegovy injection/tablets and Zepbound KwikPen. Single-dose Zepbound vials/pens are excluded.
$50 per monthly drug supply when eligible. Clinical-service charges are separate.
No. Bridge copays do not count toward those Part D thresholds.
Adults with qualifying drug coverage and specified BMI/condition criteria; see the detailed eligibility section and Medicare’s current exclusions.
Extra Help does not lower the Bridge copay.
Discuss care with a prescriber; they send the prescription and complete authorization when requested. The pharmacy processes the fill.
The demonstration ends December 31, 2027; continued price or coverage is not guaranteed.
The Bridge offers specified approved products for eligible people. Compare actual clinical options and total costs rather than assume all cash or compounded arrangements are equivalent.